- Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).
- Sales increased by 5% in Danish kroner and by 12% at CER to
DKK 66.8 billion . Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER). - Sales within Diabetes and Obesity care increased by 5% in Danish kroner to
DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER). - In
June 2021 , Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from theUS Food and Drug Administration (FDA) for weight management in adults living with obesity. - For the 2021 outlook, sales growth is now expected to be 10-13% at CER (previously 6-10%), and operating profit growth is now expected to be 9-12% at CER (previously 5-9%). Sales growth reported in Danish kroner is still expected to be 4 percentage points lower than at CER and operating profit growth reported in Danish kroner is now expected to be 5 percentage points lower than at CER.
PROFIT AND LOSS | H1 2021 | H1 2020 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 66,845 | 63,881 | 5 % | 12 % |
Operating profit | 29,761 | 30,140 | (1%) | 9% |
Net profit | 24,746 | 22,522 | 10% | N/A |
Diluted earnings per share (in DKK) | 10.71 | 9.58 | 12% | N/A |
* CER: Constant exchange rates (average 2020).
On
About
Financial calendar | |
Financial statement for the first nine months of 2021 | |
Financial statement for 2021 |
Contacts for further information | ||
Media: | ||
+45 3079 3883 | mkd@novonordisk.com | |
+1 609 664 7308 | mzyb@novonordisk.com | |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077 2253 | dhel@novonordisk.com |
+1 848 213 3219 | mjhr@novonordisk.com |
Company announcement No 48 / 2021
Attachment
- PR210804_Q2_2021
© OMX, source